A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia

查看全文 作　　者：Simon;Z.;He;Samantha;Busfield;David;S.;Ritchie;Mark;S.;Hertzberg;Simon;Durrant;Ian;D.;Lewis;Paula;Marlton;Andrew;J.;McLachlan;Ian;Kerridge;Kenneth;F.;Bradstock;Glen;Kennedy;Andrew;W.;Boyd;Trina;M.;Yeadon;Angel;F.;Lopez;Hayley;S.;Ramshaw;Harry;Iland;Simone